NCT04644809

A Study of LY3561774 in Participants With Dyslipidemia

A Single-Ascending and Repeat-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3561774

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 74 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is a 3-part study. In Parts A and B, the main purpose is to evaluate the safety and tolerability of the study drug known as LY3561774 in participants with dyslipidemia (high blood fat levels). How the body processes the study drug and the effect of the study drug on blood fat levels will also be investigated. Part C will mainly evaluate the safety and tolerability of LY3561774 as well as how the body processes the study drug in Japanese participants. The study may last up 52, 56 and 28 weeks for each participant in Parts A, B and C, respectively. There are up to 22, 26 and 16 visits in Parts A, B and C, respectively.

Conditions

• Dyslipidemias

Interventions

Type	Name	Description
DRUG	LY3561774	Administered SC.
DRUG	Placebo	Administered SC.

Timeline

• Start date: 2020-11-30
• Primary completion: 2022-05-17
• Completion: 2022-05-17
• First posted: 2020-11-25
• Last updated: 2022-08-10

Locations

5 sites across 1 country: United States

Regulatory

• FDA-regulated drug study